Abstract
Diffuse malignant peritoneal mesothelioma is a rare and lethal disease. Locoregional treatments combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) seem to improve prognosis. Methods: Cytoreductive surgery and HIPEC was performed in 22 patients at the Centre Hospitalier-Lyon Sud between 1989 and 2006. A retrospective analysis of survival was carried out to assess clinical and histological prognostic factors. Results: Nineteen patients with diffuse malignant peritoneal mesothelioma were included (16 epithelial, 3 biphasic and 3 multicystic forms). Sixteen patients presented stage 3 or 4 peritoneal carcinomatosis according to the Gilly classification. Optimal cytoreductive surgery was performed for 11 patients (complete macroscopic resection or residual tumor nodules less than 2.5mm). No post-operative deaths occurred but 9 patients (47%) presented grade III or IV post-operative complications. The overall median survival was 36.9 months; completeness of cytoreduction was the only significant prognostic factor. Conclusion: Cytoreductive surgery combined with HIPEC may improve the length of survival for patients with diffuse malignant peritoneal mesothelioma; such patients should be treated in specialized centers.
Translated title of the contribution | Peritoneal mesothelioma: Treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy |
---|---|
Original language | French |
Pages (from-to) | 447-453 |
Number of pages | 7 |
Journal | Journal de Chirurgie |
Volume | 145 |
Issue number | 5 |
DOIs | |
State | Published - 2008 |
Keywords
- Cytoreductive surgery
- Hyperthermic intraperitoneal chemotherapy
- Peritoneal mesothelioma
- Treatment
ASJC Scopus subject areas
- Surgery